Indaptus Therapeutics, Inc.
Business
Indaptus Therapeutics is a clinical-stage biotechnology company developing a novel, patented immunotherapy based on systemically-administered attenuated and killed non-pathogenic Gram-negative bacteria designed to activate both innate and adaptive immune responses for cancer and viral infections. The company's lead candidate, Decoy20, has completed initial Phase 1 clinical dosing as monotherapy and was evaluated in combination with an anti-PD-1 antibody; both studies have been discontinued with no current plans for new clinical trials. Indaptus operates virtually with a team of consultants and has historically funded operations through equity offerings.
Summary from 10-K filed 2026-03-17
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Research and development | 9 | 7 | 8 | 6 | 3 | |
| General and administrative | 10 | 8 | 9 | 9 | 5 | |
| Total operating expenses | 20 | 15 | 16 | 15 | 8 | |
| Loss from operations | −20 | −15 | −16 | −15 | −8 | |
| Other income, net | 138,018 | 343,724 | — | — | — | |
| Change in fair value of convertible promissory notes | −1 | — | — | — | — | |
| Net loss | −21 | −15 | −15 | −14 | −8 | |
| Net loss available to common stockholders per share of common stock, basic | −21.58 | −44.96 | −1.83 | −1.73 | −1.89 | |
| Net loss available to common stockholders per share of common stock, diluted | −21.58 | −44.96 | −1.83 | −1.73 | — | |
| Weighted average number of shares used in calculating net loss per share, basic | 966,124 | 334,133 | 8 | 8 | 4 | |
| Weighted average number of shares used in calculating net loss per share, diluted | 966,124 | 334,133 | 8 | 8 | — |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 9 | 6 | 13 | 10 | 39 | |
| Prepaid expenses and other current assets | 802,540 | 831,577 | 633,156 | 811,433 | 1 | |
| Total current assets | 9 | 7 | 14 | 27 | 40 | |
| Right-of-use asset | — | 82,175 | 173,206 | 79,294 | 169,088 | |
| Other assets - deposits to third parties | — | 638,251 | 754,728 | 738,251 | 16,477 | |
| Total non-current assets | — | 720,426 | 928,669 | 819,564 | 189,365 | |
| Total assets | 9 | 7 | 15 | 28 | 41 | |
| Accounts payable and other current liabilities | 6 | 3 | 3 | 3 | 5 | |
| Operating lease liability, current portion | — | 84,164 | 101,705 | 80,494 | 96,465 | |
| Total current liabilities | 6 | 3 | 3 | 3 | 5 | |
| Commitments and contingencies (Note 8) | — | — | — | — | — | |
| Common stock: $0.01 par value, 200,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 2,167,324 shares issued and outstanding as of December 31, 2025 and 428,799 shares issued and outstanding as of December 31, 2024 | 21,674 | 4,288 | 84,011 | 84,011 | 82,586 | |
| Preferred stock: $0.01 par value, 5,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 1,000,000 shares issued and outstanding as of December 31, 2025 and no shares issued and outstanding as of December 31, 2024 | 10,000 | — | — | — | — | |
| Additional paid in capital | 84 | 64 | 57 | 54 | 51 | |
| Accumulated deficit | −81 | −60 | −45 | −30 | −16 | |
| Total stockholders equity | 3 | 4 | 12 | 25 | 36 | |
| Total liabilities and stockholders equity | 9 | 7 | 15 | 28 | 41 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation | — | 735 | 1,284 | 1,781 | 1,403 | |
| Stock-based compensation | 1 | 2 | 3 | 3 | 2 | |
| Prepaid expenses and other current and non- current assets | 667,288 | −81,944 | 161,800 | 295,220 | −837,917 | |
| Accounts payable and other current liabilities | 3 | 474,057 | — | — | — | |
| Operating lease right-of-use asset and liability, net | −1,989 | 142 | 647 | 961 | 240 | |
| Net cash used in operating activities | −15 | −12 | −13 | −13 | −11 | |
| Proceeds from issuance of convertible promissory notes | 6 | — | — | — | — | |
| Proceeds from issuance of shares of common stock and warrants | 6 | 6 | — | — | — | |
| Proceeds from issuance of preferred stock | 6 | — | — | — | — | |
| Proceeds from exercise of pre-funded warrants | 1,908 | — | — | — | 27,273 | |
| Issuance costs | −569,465 | −762,703 | — | — | — | |
| Net cash provided by financing activities | 18 | 5 | — | — | 48 | |
| Net increase (decrease) in cash and cash equivalents | 3 | −8 | 4 | −30 | 37 | |
| Transaction costs in accounts payable and other current liabilities | — | 163,333 | — | — | — | |
| Settlement of convertible promissory notes | 7 | — | — | — | — | |
| Issuance of commitment shares | 109 | — | — | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Indaptus Therapeutics, Inc.'s CIK number?
Indaptus Therapeutics, Inc.'s SEC CIK number is 0001857044 (1857044). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Indaptus Therapeutics, Inc.'s SEC filings?
All of Indaptus Therapeutics, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Indaptus Therapeutics, Inc. last report earnings?
Indaptus Therapeutics, Inc. (INDP) most recently filed an earnings 8-K with the SEC on May 15, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001493152-26-023344). This is Indaptus Therapeutics, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Indaptus Therapeutics, Inc.'s most recent earnings 8-K?
Indaptus Therapeutics, Inc.'s latest earnings 8-K (Item 2.02) was filed May 15, 2026 under accession 0001493152-26-023344. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Indaptus Therapeutics, Inc.'s latest earnings 8-K →
Look up any company's CIK number →